Abstract 2131
Background
Upregulation of the receptor tyrosine kinase Axl has been linked with both a reduced response to immune checkpoint blockade as well as the development of therapy resistance to BRAF directed therapies in melanoma. Bemcentinib is a first-in-class orally bioavailable selective inhibitor of Axl which is currently being explored in several phase II clinical trials. BGBIL006 (NCT02872259) is an open label phase Ib/II trial designed to explore whether combinations with bemcentinib improves ORR and duration of response compared to standard of care therapies in patient (pts) with metastatic melanoma (MM).
Trial design
Patients are randomized 2:1 to receive D/T or pembro +/- bemcentinib, respectively, based on mutation status and tumour load. BRAF positive pts are allowed to switch D/T with pembrolizumab and vice versa upon progression. Tumour responses are assessed per investigator using RECIST v1.1. Plasma protein biomarker levels are measured using the DiscoveryMap v3.3 panel (Myriad RBM) in pts pre-dose and at C2D1. In June 2019, a formal interim analysis of clinical safety and efficacy data will be performed when at least 20 randomised patients have completed up to 12 cycles of treatment. Currently, 50 pts (92 planned) have been enrolled in the trial. Tolerability of the bemcentinib RP2D (200 mg daily) in combination with either D/T or pembro, and AE profiles for either therapeutic approach alone will be reported. Protein biomarkers candidates predictive of pt benefit following treatment and pre/post treatment changes of soluble proteins will be presented. Preliminary efficacy outcome data and safety data from the first formal preplanned interim analysis will be presented together with the recommendations from the Data Monitoring Committee.
Clinical trial identification
NCT02872259.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Research Council Norway.
Disclosure
O. Straume: Travel / Accommodation / Expenses: BerGenBio. J.B. Lorens: Shareholder / Stockholder / Stock options: BerGenBio ASA. G. Gausdal: Full / Part-time employment: BerGenBio ASA. All other authors have declared no conflicts of interest.
Resources from the same session
2115 - Preclinical in vivo screening to predict responder patients depend on EGFR status
Presenter: Yejin Kim
Session: Poster Display session 3
Resources:
Abstract
3349 - Interplay between miR-17-5p and MALAT-1 Shapes The Cytokine Storm in Triple Negative Breast Cancer (TNBC) Tumor Microenvironment
Presenter: Raghda Soliman
Session: Poster Display session 3
Resources:
Abstract
4014 - Clinical verification on the relationship between lipid metabolism and the immune microenvironment of breast cancer
Presenter: Wataru Goto
Session: Poster Display session 3
Resources:
Abstract
4158 - The clinical and transcriptional signatures of human CD204 reveal an applicable marker for tumor associated macrophage in breast cancer
Presenter: Yunjie He
Session: Poster Display session 3
Resources:
Abstract
5392 - Activated effector T cells co-expressing multiple inhibitory receptors (IRs) are enriched in the tumor immune microenvironment in high grade serous ovarian cancer (HGSOC)
Presenter: Alice Bergamini
Session: Poster Display session 3
Resources:
Abstract
2617 - Oncolytic reovirus as a new anti-tumor strategy in castration resistant prostate cancer
Presenter: Yunlim Kim
Session: Poster Display session 3
Resources:
Abstract
2995 - Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21
Presenter: Ali Memarian
Session: Poster Display session 3
Resources:
Abstract
3597 - Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
Presenter: Christophe Borg
Session: Poster Display session 3
Resources:
Abstract
3430 - Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy
Presenter: Juan Marín Jiménez
Session: Poster Display session 3
Resources:
Abstract
1995 - ¬¬Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy
Presenter: Hansol Lee
Session: Poster Display session 3
Resources:
Abstract